Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases.
It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania. The company trades on NASDAQ exchange. The company headquarter is located in Philadelphia, Pennsylvania. The company was established in the 2017.
| Ticker | PASG |
| Long Name | Passage Bio, Inc. |
| Short Name | Passage Bio |